Letter from the Executive Director

Caldwell, Katy
December 2012
Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p3
An introduction is presented in which the author discusses various reports within the issue including one about adherence to Truvada as pre-exposure prophylaxis (PrEP), another one about a PrEP trial in gay and bisexual men and transgender women, and one about integrating PrEP into practice.


Related Articles

  • Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen: A Guide to Its Use in HIV-1 Infection. Lyseng-Williamson, Katherine A.; Scott, Lesley J. // Clinical Drug Investigation;2012, Vol. 32 Issue 10, p715 

    The once-daily, single-tablet regimen of emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Evipleraâ„¢ [EU]; Compleraâ„¢ [US]) provides a convenient option for antiretroviral therapy in treatment-naive patients with HIV-1 infection. In well designed trials in this patient...

  • Who's prepared to make PrEP work? Mascolini, Mark // Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p5 

    Tenofovir/emtricitabine (TDF/FTC) won FDA approval for preexposure prophylaxis (PrEP) after three placebo-controlled trials demonstrated that once-daily TDF/FTC lowers HIV acquisition risk in gay and bisexual men and heterosexual women and men. In the one trial that found no HIV protection with...

  • HIV Pre-exposure Prophylaxis: Clinical Implications and Real-World Effectiveness. Julius Li; Dufren, Staci L.; Okulicz, Jason F. // Journal of AIDS & Clinical Research;2012, Vol. 3 Issue 9, Special section p1 

    The use of tenofovir-emtricitabine as pre-exposure prophylaxis (PrEP) represents the latest strategy to prevent the acquisition of HIV by uninfected individuals. Despite clinical trials exhibiting significant risk reductions with PrEP, several limitations may hinder its real-world effectiveness....

  • A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. Corneli, Amy L.; McKenna, Kevin; Headley, Jennifer; Ahmed, Khatija; Odhiambo, Jacob; Skhosana, Joseph; Meng Wang; Agot, Kawango // Journal of the International AIDS Society;2014 Supplement 2, Vol. 17 Issue Supp 2, p1 

    Introduction: Risk perception is a core construct in many behaviour change theories in public health. Individuals who believe they are at risk of acquiring an illness may be more likely to engage in behaviours to reduce that risk; those who do not feel at risk may be unlikely to engage in risk...

  • Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report. Malahleha, Mookho; Ahmed, Khatija; Deese, Jennifer; Nanda, Kavita; van Damme, Lut; De Baetselier, Irith; Burnett, Rosemary J. // Journal of Medical Case Reports;9/28/2015, Vol. 9 Issue 1, p1 

    Introduction: The FEM-PrEP trial was a pre-exposure prophylaxis clinical trial to test the safety and efficacy of Truvada (tenofovir disoproxil fumarate and emtricitabine) in the prevention of human immunodeficiency virus infection. Because Truvada can suppress hepatitis B virus...

  • Safety, Adherence and Acceptability of Intermittent Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis (PrEP) among HIV-Uninfected Ugandan Volunteers Living in HIV-Serodiscordant Relationships: A Randomized, Clinical Trial. Kibengo, Freddie M.; Ruzagira, Eugene; Katende, David; Bwanika, Agnes N.; Bahemuka, Ubaldo; Haberer, Jessica E.; Bangsberg, David R.; Barin, Burc; Rooney, James F.; Mark, David; Chetty, Paramesh; Fast, Patricia; Kamali, Anatoli; Priddy, Frances H. // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Background:Efficacy of oral pre-exposure prophylaxis (PrEP) in prevention of HIV acquisition has been evaluated using a daily regimen. However, adherence to long term daily medication is rarely perfect. Intermittent regimen may be a feasible alternative. Preclinical studies have demonstrated...

  • Change in Vitamin D Levels Occurs Early after Antiretroviral Therapy Initiation and Depends on Treatment Regimen in Resource-Limited Settings. Havers, Fiona P.; Detrick, Barbara; Cardoso, Sandra W.; Berendes, Sima; Lama, Javier R.; Sugandhavesa, Patcharaphan; Mwelase, Noluthando H.; Campbell, Thomas B.; Gupta, Amita // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    Study Background: Vitamin D has wide-ranging effects on the immune system, and studies suggest that low serum vitamin D levels are associated with worse clinical outcomes in HIV. Recent studies have identified an interaction between antiretrovirals used to treat HIV and reduced serum vitamin D...

  • Weighing risks of TDF/FTC PrEP side effects in people without HIV. Mascolini, Mark // Research Initiative/Treatment Action!;Winter2012, Vol. 17 Issue 2, p41 

    Prescribing tenofovir/emtricitabine (TDF/FTC) as PrEP raises questions about side effect risks in HIV-negative people. Side effects that arise in the first weeks of PrEP--nausea, abdominal cramping, vomiting, dizziness, headache, and fatigue--usually resolve without withdrawing TDF/FTC. But...

  • Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202. Grant, Philip M.; Tierney, Camlin; Budhathoki, Chakra; Daar, Eric S.; Sax, Paul E.; Collier, Ann C.; Fischl, Margaret A.; Zolopa, Andrew R.; Balamane, Maya; Katzenstein, David // HIV Clinical Trials;Nov/Dec2013, Vol. 14 Issue 6, p284 

    Background: ACTG A5202 randomized treatment-naïve individuals to tenofovir-emtricitabine (TDF/FTC) or abacavir-lamivudine (ABC/3TC) combined with efavirenz (EFV) or atazanavir/ritonavir (ATV/r). Individuals in the high screening viral load (VL) stratum (≥⃒100,000 copies/mL) had increased...


Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics